Business Context and Reporting Period
Company: Emergent BioSolutions Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 29, 2008 (Event Date: July 21, 2008)
Subject: Termination of a Material Definitive Agreement with Protein Sciences Corporation ("PSC").
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The only specific financial figures disclosed relate to the transaction in question:
- Loan to PSC: $10 million (previously provided by Emergent to PSC).
- Potential Termination Fee: $1.5 million (PSC may be entitled to this fee under certain termination circumstances, though Emergent disputes this).
Material Changes
On July 21, 2008, PSC sent a letter purporting to terminate the Asset Purchase Agreement dated May 26, 2008. Under this agreement, Emergent was set to acquire substantially all of PSC's assets, including:
- FluBlok®, a Phase III recombinant influenza vaccine candidate.
- PSC's interest in a manufacturing facility in Meriden, Connecticut.
- PSC's baculovirus expression vector system (BEVS) technology and related product candidates.
PSC alleged Emergent breached the agreement by failing to provide additional funding beyond the $10 million loan and by disclosing confidential information during pending litigation. Emergent disputes these allegations, asserting the termination is invalid and ineffective due to PSC's material breaches of representations and covenants.
Outlook, Risks, and Contingencies
Management Commentary: Emergent maintains that PSC has no right to terminate the agreement. The company argues that the agreement does not require further funding and that providing discretionary funds would be inappropriate given PSC's alleged fraudulent conduct.
Legal Contingency: A lawsuit is pending in the Supreme Court of New York County (Emergent BioSolutions et al. v. Protein Sciences Corporation, et al., Index No. 650221/2008). Emergent contends that PSC's claim regarding the disclosure of confidential information is unsupported.
Financial Risk: While PSC could potentially claim a $1.5 million termination fee, Emergent does not believe the current circumstances warrant such payment.
Investor Verification Checklist
- Verify the status of the pending litigation in the Supreme Court of New York County (Index No. 650221/2008).
- Confirm whether the $10 million loan to PSC remains outstanding or has been reclassified due to the dispute.
- Monitor for any court rulings regarding the validity of PSC's termination notice and the potential $1.5 million fee.
- Assess the impact of the failed acquisition on Emergent's pipeline, specifically regarding the FluBlok® vaccine candidate.